Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma

Alvaro J. Alencar, Alexandre V. Hirayama, Diego V. Clé, Marco Aurélio Salvino, Guilherme Perini, Celso Arrais, Otávio Baiocchi, Leonardo Carvalho Palma, Iago Colturato, Jorge Vaz, Ricardo Chiattone, Marcos de Lima, Jayr Schmidt Filho, Samir Nabhan, Vanderson Rocha, Renato L. Guerino-Cunha, Carlos S. Chiattone

Research output: Contribution to journalArticlepeer-review

Abstract

The treatment and evolution of B-cell non-Hodgkin lymphoma (B-NHL) has undergone important changes in the last years with the emergence of targeted therapies, such as monoclonal antibodies, small molecules, antibody-drug conjugates, and bispecific antibodies. Nevertheless, a significant portion of patients remains refractory or relapsed (R/R) to the new therapeutic modalities, representing thus an unmet medical need. The use of CAR-T cells for the treatment of B-NHL patients has shown to be a promising therapy with impressive results in patients with R/R disease. The expectations are as high as the imminent approval of CAR-T cell therapy in Brazil, which it is expected to impact the prognosis of R/R B-NHL. The aim of this manuscript is to offer a consensus of specialists in the field of onco-hematology and cellular therapy, working in Brazil and United States, in order to discuss and offer recommendations in the present setting of the use of CAR-T cells for patients with B-NHL.

Original languageEnglish (US)
Pages (from-to)S22-S29
JournalHematology, Transfusion and Cell Therapy
Volume43
DOIs
StatePublished - Nov 2021

Keywords

  • Adoptive cellular therapy
  • Advanced cellular therapy
  • CAR-T cells
  • Cellular therapy
  • Immunotherapy
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

Fingerprint

Dive into the research topics of 'Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this